Myasthenia gravis (MG), an autoimmune neuromuscular disorder, may be a risk factor for severe COVID-19. We conducted an observational retrospective study with 15 consecutive adult MG patients admitted with COVID-19 at four hospitals in São Paulo, Brazil. Most patients with MG hospitalized for COVID-19 had severe courses of the disease: 87% were admitted in the intensive care unit, 73% needed mechanical ventilation, and 30% died. Immunoglobulin use and the plasma exchange procedure were safe. Immunosuppressive therapy seems to be associated with better outcomes, as it might play a protective role.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, Immunosuppression, myasthenia gravis, Neuromuscular disorders, 【초록키워드】 Brazil, Hospitalized, intensive care, severe COVID-19, mechanical ventilation, hospital, risk factor, outcomes, Retrospective study, Patient, plasma, Autoimmune, immunosuppressive therapy, Safe, protective role, disorder, Course, died, Most patient, conducted, with COVID-19, 【제목키워드】 clinical, Myasthenia,
【저자키워드】 COVID-19, SARS-CoV-2, Immunosuppression, myasthenia gravis, Neuromuscular disorders, 【초록키워드】 Brazil, Hospitalized, intensive care, severe COVID-19, mechanical ventilation, hospital, risk factor, outcomes, Retrospective study, Patient, plasma, Autoimmune, immunosuppressive therapy, Safe, protective role, disorder, Course, died, Most patient, conducted, with COVID-19, 【제목키워드】 clinical, Myasthenia,